trending Market Intelligence /marketintelligence/en/news-insights/trending/l5j9yhbrozwo7zel7_uufg2 content esgSubNav
In This List

Proteostasis plans common stock offering

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

Blog

Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback

Infographic

Infographic: The Big Picture 2023 Sustainability Outlook

Blog

The Big Picture for 2023: Assessing Investment Trends and the Impact of Investor Activism


Proteostasis plans common stock offering

Proteostasis Therapeutics Inc. plans to sell 9 million common shares in an underwritten public offering

The company plans to grant the underwriters an option to buy up to an additional 15%, or 1,350,000 common shares, in the public offering.

Leerink Partners and RBC Capital Markets are acting as joint book-running managers, and H.C. Wainwright & Co. is acting as lead manager for the offering.